The role of common genetic risk variants in Parkinson disease

Clinical Genetics

Volumn 72, Issue 5, 2007, Pages 387-393

  Tan, Eng King ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Disease; Familial; Gene; Neurodegeneration; Parkinson; Sporadic; Variant

Indexed keywords

ACETYLCYSTEINE; ACETYLCYSTEINE 2; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; GLUTATHIONE TRANSFERASE; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN; TRANSFER RNA; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; ENZYME DEGRADATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MISSENSE MUTATION; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIA; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RESEARCH DESIGN; RISK FACTORS;

EID: 35348820061     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00890.x     Document Type: Review

References (47)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983: 219 (4587): 979-980.
2. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997: 276 (5321): 2045-2047.
3. Tan EK, Jankovic J. Genetic testing in Parkinson disease: Promises and pitfalls. Arch Neurol 2006: 63 (9): 1232-1237.
4. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005: 366 (9493): 1315-1323.
5. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000: 55 (4): 533-538.
6. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002: 111 (2): 209-218.
7. Maraganore DM, Lesnick TG, Elbaz A et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004: 55 (4): 512-521.
8. Tan EK, Puong KY, Fook-Chong S et al. Case-control study of UCHL1 S18Y variant in Parkinson's disease. Mov Disord 2006: 21 (10): 1765-1768.
9. Healy DG, Abou-Sleiman PM, Casas JP et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol 2006: 59 (4): 627-633.
10. Ibanez P, Bonnet AM, Debarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004: 364 (9440): 1169-1171.
11. Fleming SM, Salcedo J, Fernagut PO et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004: 24 (42): 9434-9440.
12. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005: 8 (5): 657-963.
13. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001: 10 (26): 3101-3109.
14. Maraganore DM, de Andrade M, Elbaz A et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006: 296 (6): 661-670.
15. Ishizawa T, Mattila P, Davies P et al. Colocalisation of tau and alpha synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003: 62: 389-397.
16. Healy DG, Abou-Sleiman PM, Lees AJ et al. Tau gene and Parkinson's disease: A case-control study and meta-analysis. J Neurol Neurosurg Psychiatry 2004: 75 (7): 962-965.
17. Facheris M, Strain KJ, Lesnick TG et al. UCHL1 is associated with Parkinson's disease: A case-unaffected sibling and case-unrelated control study. Neurosci Lett 2005: 381 (1-2): 131-134.
18. van der Walt JM, Noureddine MA, Kittappa R et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 2004: 74 (6): 1121-1127.
19. Kang SJ, Scott WK, Li YJ et al. Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson disease. Mov Disord 2006: 21 (12): 2175-2180.
20. Maraganore DM, de Andrade M, Lesnick TG et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005: 77 (5): 685-693.
21. Li Y, Rowland C, Schrodi S et al. A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. Am J Hum Genet 2006: 78 (6): 1090-1092. author reply 1092-1094.
22. Elbaz A, Nelson LM, Payami H et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: A large-scale international study. Lancet Neurol 2006: 5 (11): 917-923.
23. Evangelou E, Maraganore DM, Ioannidis JP. Meta-analysis in genome-wide association datasets: Strategies and application in Parkinson disease. PEoS ONE 2007: 7 (2): e196.
24. Mata IF, Kachergus JM, Taylor JP et al. LRRK2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005: 6: 171-177.
25. Skipper L, Li Y, Bonnard C et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 2005: 14 (23): 3549-3556.
26. Biskup S, Mueller JC, Sharma M et al. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann Neurol 2005: 58: 905-908.
27. Paisan-Ruiz C, Evans EW, Jain S et al. Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. J Med GeEet 2006: 43 (2): e9.
28. Paisan-Ruiz C, Lang AE, Kawarai T et al. LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. Neurology 2005: 65: 696-700.
29. Di Fonzo A, Wu-Chou YH, Lu CS et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006: 7 (3): 133-138.
30. Tan EK, Zhao Y, Skipper L et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: Genetic and functional evidence. Hum Genet 2007: 120 (6): 857-863.
31. Funayama M, Li Y, Tomiyama H et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007: 18 (3): 273-275.
32. Farrer MJ, Stone JT, Lin CH et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 2007: 13 (2): 89-92.
33. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006: 22 (6): 47.
34. Tan EK, Fook-Chong S, Yi Z. Comparing LRRK2 Gly2385Arg carriers with noncarriers. Mov Disord 2007: 22 (3): 749-750.
35. Jaleel M, Nichols RJ, Deak M et al. LRRK2 phosphorylates moesin at Thr558; characterisation of how Parkinson's disease mutants affect kinase activity. Biochem J 2007: 405 (2): 307-317.
36. Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006: 354 (4): 424-425.
37. Lesage S, Durr A, Tazir M et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006: 354 (4): 422-423.
38. Tan EK, Skipper L, Tan L, Liu JJ. LRRK2 G2019S founder haplotype in the Chinese population. Mov Disord 2007: 22 (1): 105-107.
39. Tan EK, Shen H, Tan LC et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005: 384 (3): 327-329.
40. Goldwurm S, Zini M, Mariani L et al. Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. Neurology 2007: 68 (14): 1141-1143.
41. Lucking CB, Chesneau V, Lohmann E et al. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch Neurol 2003: 60 (9): 1253-1256.
42. Tan EK, Puong KY, Chan DK et al. Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: Clinical association. Hum Genet 2005: 118 (3-4): 484-488.
43. Conrad DF, Jakobsson M, Coop G et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 2006: 38 (11): 1251-1260.
44. de Bakker PI, Burtt NP, Graham RR et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006: 38 (11): 1298-1303.
45. Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: First stage analysis and public release of data. Lancet Neurol 2006: 5 (11): 911-916.
46. Ioannidis JP, Gwinn M, Little J et al. A road map for efficient and reliable human genome epidemiology. Nat Genet 2006: 38 (1): 3-5.
47. Lesnick TG, Papapetropoulos S, Mash DC et al. A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. PLoS Genet 2E07: 3 (6): e98.